Can I stop taking Sotatercept-Winrevair once I take it?

Sotatercept-Winrevair is a class of innovative targeted drugs that have received widespread attention around the world in recent years. It improves the structure and function of pulmonary blood vessels by inhibiting the activin signaling pathway and is approved by the FDA for the treatment of adult pulmonary arterial hypertension (PAH). Different from traditional vasodilators, soltercept not only improves hemodynamics in the short term, but may also have a sustained inhibitory effect on pulmonary vascular remodeling. Therefore, it is considered to be a new therapeutic drug that can "change the course of the disease" in terms of mechanism. One concern many patients have is whether this medication cannot be stopped once it is started.

From the current point of view, Sotercept is not a "lifelong dependence on the drug" in the simple sense. Its application needs to be dynamically adjusted based on the patient's specific condition, pulmonary artery pressure control, and tolerance. Pulmonary hypertension is a chronic progressive disease. If the drug is simply stopped, there is a real risk of disease rebound or symptom aggravation. Because soltercept works by blocking specific signaling pathways, once the drug is withdrawn, vascular remodeling may become active again, and the patient's clinical benefit may be attenuated. Therefore, it is not clinically recommended to interrupt medication at will.

However, this does not mean that patients must use the drug "for life." Doctors will comprehensively evaluate the patient's long-term response and side effects. Some people may adjust the dosage after the disease is better controlled, or even try to discontinue the drug or combine it with other drugs under strict monitoring. The real key is individualized management, rather than a one-size-fits-all view that once you take Sotrecept, you must never stop it.

From experience, Sotecept is more positioned as part of long-term maintenance treatment, and is especially suitable for use in combination with existingPAH standard treatments to improve patients’ exercise tolerance and delay the progression of the disease. It is important for patients to understand that the value of these drugs lies not in short-term results but in long-term benefits.

Reference materials:https://www.drugs.com/mtm/sotatercept.html